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Positive allosteric modulators of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPARs) are small molecules that decrease deactivation of AMPARs via an allosteric site. These mole-
cules keep the receptor in an active state. Interestingly, this type of modulator has been proposed for
treating cognitive decline in ageing, dementias, and Alzheimer's disease (AD). S 47445 (8-cyclopropyl-3-
[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione) is a novel
AMPAR positive allosteric modulator (AMPA-PAM). Here, the mechanisms by which S 47445 could
improve synaptic strength and connectivity were studied and compared between young and old mice. A
single oral administration of S 47445 at 10 mg/kg significantly increased long-term potentiation (LTP) in
CA3-CA1 hippocampal synapses in alert young mice in comparison to control mice. Moreover, chronic
treatment with S 47445 at 10 mg/kg in old alert animals significantly counteracted the deficit of LTP due
to age. Accordingly, chronic treatment with S 47445 at 10 mg/kg seems to preserve synaptic cytoarch-
itecture in old mice as compared with young control mice. It was shown that the significant decreases in
number and size of pre-synaptic buttons stained for VGlut1, and post-synaptic dendritic spines stained
for spinophilin, observed in old mice were significantly prevented after chronic treatment with 10 mg/kg
of S 47445. Altogether, by its different effects on LTP, VGlut1-positive particles, and spinophilin, S 47445 is
able to modulate both the structure and function of hippocampal excitatory synapses known to be
involved in learning and memory processes. These results open a new window for the treatment of
specific age-dependent cognitive decline and dementias such as AD.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer's disease (AD), the most common form of dementia,
is a complex neurodegenerative disorder clinically characterized by
a progressive loss of cognitive functions and alteration of different
behaviors (Rampa et al., 2013). The currently available symptomaticPablo de Olavide University,
r Ltd. This is an open access articleAD treatments such as acetylcholinesterase inhibitors and mem-
antine have shown efficacy in numerous randomized controlled
trials, but the magnitude of effects is limited or restricted to a
certain population of patients as observed in comprehensive meta-
analysis (Rampa et al., 2013). Moreover, they induced clear sec-
ondary effects involving gastrointestinal disorders (Tricco et al.,
2013). Thus, pharmacological targeting of other molecular path-
ways remains necessary in order to have more-effective drugs for
AD patients (Partin, 2015; Reuillon et al., 2016; Tayeb et al., 2012).
Among glutamatergic pathways, the positive modulation of a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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actors of long-term potentiation (LTP), a form of synaptic plasticity
that mediates learning and memory (Bliss and Collingridge, 1993;
Brown and Banks, 2015; Chater and Goda, 2014; Gruart et al.,
2015; Huganir and Nicoll, 2013; Whitlock et al., 2006). Moreover,
a clear dysfunction of central glutamatergic pathways occurs dur-
ing ageing and dementias such as AD (Henley andWilkinson, 2013;
Robbins and Murphy, 2006; Rudy et al., 2015). N-methyl-D-aspar-
tate (NMDA) and AMPA receptors are reported to be dramatically
reduced at synapses from human AD postmortem brain tissues
(Gong et al., 2009) and Ab impairs synaptic plasticity by several
mechanisms impacting glutamate receptorsdnotably, by inducing
endocytosis of glutamate receptors and activating signaling path-
ways involved in long-term depression and spine loss (Gasparini
and Dityatev, 2008; Parameshwaran et al., 2008).
Herein, we report the in vivo characterization of S 47445 (8-
cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxa-
zino[6,5-g][1,2,3]benzotriazine-4,9-dione), a novel selective posi-
tive allosteric modulator of the AMPA receptors (AMPA-PAM)
discovered through collaboration between Cortex Pharmaceuticals
and Servier (Fig. 1). In a preliminary study, the mechanism of action
of S 47445 towards AMPA receptors and its selectivity were tested
on AMPA, NMDA, and kainate receptors expressed in Xenopus laevis
oocytes (Danober et al., 2016). Subsequently, and based on the
glutamatergic dysfunctions observed in AD, this study was focused
on hippocampal CA3-CA1 synaptic plasticity and connectivity in
young (3-months-old) and old (14-months-old) freely moving
mice, and assessed whether S 47445 corrects the aged deficit after
either acute or chronic treatment. The micro-cytoarchitecture in
hippocampal and cortical tissue was also evaluated in order to have
a wider perspective of the drug's effects since preclinical and
clinical evidence had shown that a functional coupling exists be-
tween hippocampal formation and prefrontal cortex and has an
important role in cognition and emotional regulation (Godsil et al.,
2013). In particular, we evaluated the drug's effect on the presyn-
aptic vesicular glutamate transporter VGlut1, which maintains the
level of glutamate stored in vesicles (Balschung et al., 2010; ChengFig. 1. Chemical structure of S 47445. Chemical name of S 47455 is 8-cyclopropyl-3-
[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-
dione.
Fig. 2. S 47445 is a powerful and selective allosteric modulator of AMPA receptors. Effec
expressed in Xenopus oocytes. Exposure to 100 mM S 47445 causes a very large potentia
receptors) compared with the response evoked in the same cell recorded in controls. Recordi
47445 causes no potentiation of the glutamate-evoked current. Similar results were observe
traces were recorded during exposure to 100 mM S 47445.et al., 2011; Fremeau et al., 2001; Wojcik et al., 2004), and on the
postsynaptic protein spinophilin, which participates in functional
plasticity in dendritic spines (Stafstrom-Davis et al., 2001), in both
young and old mice.
2. Material and methods
2.1. Electrophysiological recordings in Xenopus laevis oocytes
Following deep anesthesia in 0.15% tricaine methanesulfonate
(MS222), a small incision was made in the lower part of the
abdomen of Xenopus laevis and the ovary was removed. Animals
were euthanatized according to the Swiss animal welfare rules
under the authorization No 27479 GE/15/16. Following standard
mechanical and enzymatic dissociation using collagenase, oocytes
were placed at 17 C in a sterile Barth solution containing (in mM)
NaCl 88, KCl 1, NaHCO3 2.4, HEPES 10, MgSO4$7H2O 0.82, Ca(NO3)2
0.33, and CaCl2 0.41, at pH 7.4, and supplemented with 20 mg/mL of
kanamycin,100 unit/mL penicillin, and 100 mg/mL streptomycin. On
the second day after dissociation, oocytes were placed in a 96-well
microtiter plate with conical bottom, and injected with 10 nL so-
lution containing the cDNA encoding for the desired receptors
(human NR1a/NR2B, human GluA1flop/GluA2flip, or human
GluK2) at a concentration of 0.2 mg/mL using the Roboinjected
(Multichannel Systems, Reutlingen, Germany). They were then
stored at 17 C until use (typically 1e2 weeks).
Electrophysiological recordings were performed at 18e20 C by
using two-electrode voltage clamp recordings with the HiClamp
automated system (Multichannel Systems, Reutlingen, Germany).
Oocytes were superfused with OR2 medium containing (in mM)
NaCl 88.5, KCl 2.5, HEPES 5, MgCl2 1, CaCl2 1.8, and Na2HPO4 1, pH
7.4. For NMDA recordings, MgCl2 was omitted from the medium.
Unless indicated, cells were held at 80 mV. Compounds were
tested by bath application. For recordings on oocytes expressing
subunits of human AMPA receptors or GluK2 or NR1a/NR2B,
application of 300 mMof glutamate or 100 mMof glutamateþ 10 mM
of glycine was first performed for 20 s, respectively. S 47445
(micronized form) was then bath-applied at 100 mM on the same
oocyte for 45 s before and 20 s during the application of glutamate.
S 47445 was dissolved in DMSO. The DMSO concentration was
below 1%, which is known to have no significant effects in the
experimental models tested (see Fig. 2).
2.2. Experimental animals
Male C57Bl6 mice were used in this study. Animals werets of S 47445 tested at human AMPA, NMDA (NR2B-containing), and kainate receptors
tion of the glutamate-evoked current at AMPA receptors (GluA1flop/GluA2flip AMPA
ngs obtained in comparable conditions at NMDA receptors (NR1a-NR2B) revealed that S
d at the kainate receptors. Gray traces were recorded in control conditions while black
A. Giralt et al. / Neuropharmacology 123 (2017) 395e409 397obtained from an official supplier (Janvier, France) and were 2 or 13
months old at their arrival. Animals were placed in the animal
house facilities of the Pablo de Olavide University (Seville, Spain) or
the Facultat de Medicina of the University of Barcelona (Barcelona,
Spain) andmaintained at an ambient temperature of 21 ± 2 C, with
the hygrometry set at 55 ± 5%. Animals were kept on a standard 12-
h light/dark cycle both before and throughout the experiments.
Studies were carried out during the lit period of the cycle. Before
electrophysiological experiments, animals were kept in a social
(n ¼ 6 animals/cage) environment, but in order to avoid any
damage of the implanted devices, they were maintained in indi-
vidual boxes after surgery. All experiments were carried out in
accordance with the current national (Spanish BOE 34/11370-421,
2013) and European rules (European Council Directive 2010/63/EU)
for the use of laboratory animals in chronic experiments and
approved by the local Ethics Committee of the Pablo de Olavide
University.
2.3. In vivo drug treatments
The micronized form of S 47445 (Servier, France) was dissolved
in a vehicle consisting of 1% (w/v) hydroxyethylcellulose and 1% (v/
v) polysorbate 80 in distilled water. Two doses of the compound
(3 mg/kg and 10 mg/kg) were selected for the initial study (input/
output curves, paired-pulse facilitation, and LTP) and then used for
all experiments. S 47445 and its vehicle were given per os (p.o.) and
intraperitoneally (i.p.) in electrophysiological and structural
studies, respectively.
2.4. Experimental groups
Young (3-months-old) and old (14-months-old) mice were used
at the time of the experiments. For electrophysiology experiments,
animals were divided in different groups (n ¼ 10 per group). Ex-
periments illustrated in Fig. 3DeF were carried out in young mice
treated with either vehicle (control) or S 47445 (3 mg/kg or 10 mg/
kg). Experiments illustrated in Figs. 4 and 5 were done in young
control mice, old control mice, and old mice treated with S 47445
(3 mg/kg and 10 mg/kg, Figs. 4 and 5, respectively). In the LTP ex-
periments, S 47445 was chronically administered for 15 days and
LTP was evoked on two occasions, on day 1 and on day 13 after the
first administration of S 47445 (Figs. 4A and 5A).
For structural experiments, different animals than those used
for LTP experiments were used, divided in the following groups
(n ¼ 5 per group): young control mice, old control mice, and old
mice treated with S 47445 (3 mg/kg or 10 mg/kg) (Figs. 6e9). All of
them received a chronic treatment (30 days), and 24 h after the last
injection, their brains were fixed for imaging analyses.
2.5. Surgery
Animals were anesthetized with 0.8e1.5% isoflurane (Astra
Zeneca, Madrid, Spain) delivered via a special mask (Cibertec,
Madrid, Spain). Once anesthetized, animals were implanted with
bipolar stimulating electrodes aimed at the right Schaffer
collateral-commissural pathway of the dorsal hippocampus (2 mm
lateral and 1.5 mm posterior to bregma; depth from brain surface,
1.0e1.5 mm; Paxinos and Franklin, 2001), and with a recording
electrode aimed at the ipsilateral stratum radiatum underneath the
CA1 area (1.2 mm lateral and 2.2 mm posterior to bregma; depth
from brain surface, 1.0e1.5 mm; Paxinos and Franklin, 2001).
Stimulating and recording electrodes were made from 50 mm,
Teflon-coated tungsten wire (Advent Research Materials, Eynsham,
UK). The final location of the recording electrode in the CA1 area
was determined following the field potential depth profile evokedby paired (40 ms of interval) pulses presented to the ipsilateral
Schaffer collateral pathway (Bliss and Gardner-Medwin, 1973;
Gruart et al., 2006). Two bare silver wires were affixed to the skull
as ground. Electrodes were connected to a 6-pin socket (RS-Ami-
data, Madrid, Spain) that was latterly fixed with dental cement to
the cranial bone (Fig. 3AeC). After surgery, animals were kept for
5e7 days in independent cages with free access to food and water
for a proper recovery.
2.6. Input/output curves and paired-pulse facilitation at the CA3-
CA1 synapse
For input/output curves (Fig. 3D), monosynaptic field excitatory
postsynaptic potentials (fEPSP) were evoked in the CA1 area by
single (100 ms, square, negative-positive) pulses applied to Schaffer
collaterals. These pulses were presented at increasing intensities
ranging from 20 mA to 500 mA, in steps of 20 mA. In order to avoid
interactions with the preceding stimulus, an interval of 30 s was
allowed between each pair of pulses (Madro~nal et al., 2007).
For the characterization of the paired-pulse facilitation at the
CA3-CA1 synapse (Fig. 3E), we used the same types of pulse indi-
cated above, but presented in pairs at increasing inter-pulse in-
tervals (10, 20, 40, 100, 200, and 500 ms). For each animal, the
stimulus intensity was set at 30e40% of the intensity necessary for
evoking a maximum fEPSP response (Gruart et al., 2006;
Gureviciene et al., 2004). Intervals between pairs of pulses were
set at ~30 s, to avoid unwanted interactions evoked by pre- or post-
synaptic mechanisms.
2.7. Long-term potentiation (LTP) evoked at the CA3-CA1 synapse
For each animal, the stimulus intensity was set at 30e40% of the
intensity necessary for evoking a maximum fEPSP responsedi.e.
well below the threshold for evoking a population spike (Gruart
et al., 2006; Madro~nal et al., 2007). Field EPSPs were recorded
prior to and following LTP induction. For LTP induction, each animal
was presented with a high-frequency stimulation (HFS) protocol
consisting of five 200 Hz,100ms trains of pulses at a rate of 1/s. This
protocol was presented six times, at intervals of 1 min. The HFS
protocol used here (combining low-intensity values and a total of
600 electric shocks) allowed us to evoke LTP lasting > 2e3 days,
without the appearance of abnormal spikes in EEG recordings and/
or overt epileptic seizures (Madro~nal et al., 2009).
As illustrated in Fig. 3F, in a first experimental step and for
baseline records, animals were stimulated at Schaffer collaterals
with single pulses, at the selected stimulus intensity, and at a rate of
3/min for 15 min. Afterwards, animals were presented with the HFS
protocol. Following the HFS session, animals were stimulated again
with single pulses applied for 60 min. After two hours, we repeated
the same 60-min recording session. Additional 30-min recordings
of fEPSPs were repeated for a further 4 days following the 1st HFS
session.
In some experiments (Figs. 4A, C and 5A, C), animals received a
2nd HFS session 13 days after the first one. All the recordings before
and after the 2nd HFS session were carried out as described above
for the 1st one, but in this case recording sessions were maintained
for up to 5 days.
2.8. Tissue fixation and immunofluorescence
Animals were transcardially perfused with 4% para-
formaldehyde solution in 0.1 M sodium phosphate, pH 7.2. The
brains were postfixed for 2 h in the same solution. Next, the fixed
tissue was cryoprotected in incrementing 10e30% sucrose/
phosphate-buffered saline (PBS) with 0.02% sodium azide, and
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(30 mm), separated 0.24 mm and containing dorsal hippocampus
and cortical tissue, were processed for immunohistochemistry.
Brain sections were washed three times in PBS. Next, slices were
permeabilized with a 15-min shaking at room temperature with
PBS buffer containing 0.3% Triton X-100 and 3% of normal goat
serum (Pierce Biotechnology, Rockford, IL, USA). Then, after three
washes, brain slices were incubated overnight with shaking at 4 C
with corresponding primary antibodies in PBS with 0.02% sodium
azide buffer: rabbit anti-VGlut1 1:500 (Synaptic Systems, Gottin-
gen, Germany) and rabbit anti-spinophilin 1:250 (Upstate,
Biotechnology, NY, USA). After primary antibody incubation, slices
were washed three times and then incubated 2 h with shaking at
room temperature with subtype-specific fluorescent secondary
antibodies: Cy3 goat anti-rabbit (1:100) from Jackson ImmunoR-
esearch (West Grove, PA). No signal was detected in controls
incubated in the absence of the primary antibody.
2.9. Imaging
VGlut1-and spinophilin-positive particles were examined as
previously described (Carreton et al., 2012; Giralt et al., 2011). The
analyses were performed by confocal microscopy using a Leica
(Mannheim, Germany) TCS SL laser scanning confocal spectral
microscope with argon and heliumeneon lasers attached to a Leica
DMIRE2 inverted microscope. Images were taken using a
63  numerical aperture (NA) objective with 4  digital zoom and
standard (one Airy disk) pinhole. Four coronal sections (30 mm in
thickness) per animal spaced 0.24 mm apart in which the neocor-
tical area M1 was represented (1.8e0.8 mm from bregma) and four
coronal sections with identical properties in which the dorsal
hippocampus was represented (1.1 to 2.1 mm from bregma)
were analyzed. For each slice, we obtained 3 fields/neocortical layer
analyzed (II/III and V) of the M1 area, and 3 fields/stratum radiatum
of CA1 and CA3 of the dorsal hippocampus. In each field, the entire
three-dimensional stack of images was obtained by use of the Z
drive present in the Leica TCS-SL microscope, and optical sections
(3/field) of 0.5 mmwere obtained separately (3 mm) in order to avoid
biased counting. The number and area of positive VGlut1 and spi-
nophilin puncta were measured using the freeware NIH ImageJ
version 1.33 by Wayne Rasband (National Institutes of Health,
Bethesda, MD). Briefly, for each section, the positive post-synaptic
cluster area was delineated based on positive pixels for VGlut1 on
one hand and the same for spinophilin on the other. The total
number of positive particles was counted and their area recorded.
2.10. Data presentation and statistical analysis
Extracellular hippocampal activity, and 1-V rectangular pulses
corresponding to stimulus presentations, were stored digitally on aFig. 3. Input/output curves, paired-pulse facilitation, and long-term potentiation (LTP)
istration of S 47445. (A) Animals were implanted with stimulating and recording electrod
times) at the top right illustrates an fEPSP recorded (Rec.) in the stratum radiatum of the CA1
illustrating the location of stimulating and recording electrodes. (C) Photomicrographs illustr
electrical pulses of increasing intensities (0.02 mAe0.50 mA) at hippocampal Schaffer colla
slopes presented characteristic sigmoid-like shapes for all experimental groups. No signi
(vehicle-treated) mice and mice treated with S 47445 (3 mg/kg and 10 mg/kg). (E) Paired-pu
to the first one at short (<40 ms) inter-stimulus intervals. No significant differences (p  0.05
47445 (3 mg/kg and 10 mg/kg). (F) LTP testing. After three sessions (15 min each) of bas
administered with either vehicle or S 47445. Forty-five min after administration, animals we
with the HFS protocol (vertical dashed line). Recording was carried out in the CA1 area for 60
after the HFS session. Additional recordings were carried out for 30 min during the next four
S 47445 at 10 mg/kg displayed significantly larger LTP values than control mice (*, p < 0.00
47445 at 3 mg/kg and control mice (p  0.051). Calibration bar in C is 200 mm. Abbreviation
gyrus. For the three experiments (D, E and F), n ¼ 10 animals/group.computer through an analog/digital converter (CED 1401 Plus,
Cambridge, UK), at a sampling frequency of 11e22 kHz and with an
amplitude resolution of 12 bits. Data were analyzed off-line for
quantification of fEPSP slopes with the help of commercial (Spike 2
and SIGAVG from CED) and home-made representation programs
(Gruart et al., 2006). The slope of evoked fEPSPs was represented as
the first derivative (volts per second) of fEPSP recordings (volts). For
this, five successive fEPSPs were averaged, and the mean value of
the slope during the rise time period (i.e., the period of the slope
between the initial 10% and the final 90% of the fEPSP) was deter-
mined. Collected data were processed for statistical analysis using
the Sigma Stat for Windows package. Unless otherwise indicated,
data are represented as the mean ± SEM. Acquired data were
analyzed using a two-way ANOVA test, with days as repeated
measure. Contrast analysis was added to further study significant
differences. For statistical analysis of the microstructural experi-
ments, we performed one-way ANOVA, and all groups were
compared with each other in pairs, using the Tukey test post hoc.
For imaging analyses, groups of young control mice and old
control mice were compared, using a Student t-test. Old mice
treated with S 47445 (3 mg/kg and 10 mg/kg) and old control mice
were compared using a one-way ANOVA. If dose effect was sig-
nificant, a post hoc Dunnett test was performed versus old control
mice. The significance level was established at p ¼ 0.05 for all tests.
3. Results
3.1. Determination of the selective modulation on AMPA receptor by
S 47445
To assess the selectivity of S 47445, its effects were evaluated
in vitro using recombinant human AMPA, NMDA, and kainate re-
ceptors expressed in Xenopus laevis oocytes. While exposure to
100 mM of S 47445 induced both a clear potentiation of the
glutamate-evoked current as well as a decay time of the response,
no detectable modification of the current amplitude or response
time course was detected at NMDA or kainate receptors (Fig. 2).
Collectively, these results corroborate the results obtained by other
experimental approaches (Danober et al., 2016) and confirm the
selectivity of the drug towards AMPA receptor and its potentiating
effect on the glutamate-evoked response at the AMPA receptors.
3.2. Functional properties of the CA3-CA1 synapse in young alert
behaving mice following the acute administration of S 47445
Available in vivo recording techniques (Gruart et al., 2006)
enabled us to study basic functional properties of hippocampal
synapses in behaving mice. As already reported (Madro~nal et al.,
2009), young control mice displayed a sigmoid-like increase of
the fEPSP-evoked amplitude in the CA3 area following a stimulus ofevoked at the CA3-CA1 synapse of young alert behaving mice after acute admin-
es located at the CA3-CA1 synapses in the right hippocampus. The record (averaged 5
area following electrical stimulation (St.) of the Schaffer (Sch.) collaterals. (B) Diagram
ating the location of stimulating (top) and recording (bottom) sites (arrows). (D) Single
terals evoked fEPSPs of increasing amplitudes at CA1 recording sites. Collected fEPSP
ficant differences (p  0.051) were observed between results obtained from control
lse stimulation of CA3-CA1 synapse evoked facilitation to the second pulse with respect
1) were observed between results obtained from control mice and mice treated with S
eline records carried out on three consecutive days (Day 3 to Day 1), mice were
re presented with an additional baseline session and stimulated at Schaffer collaterals
min after the HFS protocol. An additional 60-min recording session was carried out 3 h
days. Considering fEPSPs recorded immediately after the HFS session, mice treated with
1). In contrast, no significant differences were observed between mice treated with S
s: D, dorsal; L, lateral; M, medial; V, ventral; CA1-3, cornus ammonis 1-3; DG, dentate
Fig. 4. Long-term potentiation (LTP) evoked at the CA3-CA1 synapse in old alert behaving mice following acute and chronic administrations of S 47445 at 3 mg/kg. (A)
Diagram of the experimental design. LTP was evoked in young control mice, old control mice, and old mice treated with S 47445 at 3 mg/kg following acute and chronic ad-
ministrations. (B) Following acute treatment administration, young control mice presented significantly larger LTP than old control mice (*, p  0.05) and old mice treated with S
47445 at 3 mg/kg (#, p  0.05). In addition, old mice treated with S 47445 at 3 mg/kg presented a larger LTP during the second part of the 1st LTP session than old control mice ($,
p  0.05). (C) Following chronic treatment administration (13 days), old mice treated with S 47445 at 3 mg/kg failed to present significantly larger LTP than young control mice
(p  0.051) and old control mice (p  0.051). Recording sessions carried out in absence of vehicle or drug administration are indicated by the double-arrowed line. For both
experiments, n ¼ 10 animals/group.
A. Giralt et al. / Neuropharmacology 123 (2017) 395e409400increasing intensity presented at Schaffer collaterals until reaching
saturating values (Fig. 3D). Animals acutely treated with S 47445
(3 mg/kg or 10 mg/kg) presented similar input/output curves to
those of control mice without significant differences between
groups [F(114,1126)¼ 0.881; p 0.051], indicating an absence of effect
of S 47445 on electrophysiological basal activity in alert behaving
mice in our study conditions.
Paired-pulse facilitation at the CA3-CA1 synapse was also
studied. It is well-known that synaptic facilitation evoked by thepresentation of a pair of pulses is a typical presynaptic short-term
plastic property of hippocampal synapses related to the process
of neurotransmitter release (Madro~nal et al., 2009; Zucker and
Regehr, 2002). As illustrated in Fig. 3E, at short inter-stimulus in-
tervals, a facilitation of the effect of the second pulsewith respect to
the fEPSP evoked by the first pulse was observed in young mice
[F(30, 270)¼ 1.017; p 0.051]. However, no significant difference was
observed following acute administration of S 47445 at either 3 mg/
kg or 10 mg/kg as compared with control mice, suggesting no
Fig. 5. Long-term potentiation (LTP) evoked at the CA3-CA1 synapse in old alert behaving mice following acute and chronic administrations of S 47445 at 10 mg/kg. (A)
Diagram of the experimental design. LTP was evoked in young control mice, old control mice, and old mice treated with S 47445 at 10 mg/kg following acute and chronic ad-
ministrations. (B) Following acute treatment administration, young control mice (*, p  0.05) and old mice treated with S 47445 at 10 mg/kg ($, p  0.05) presented significantly
larger LTP than old control mice. (C) Following chronic treatment administration (13 days), old mice treated with S 47445 at 10 mg/kg presented significantly larger and longer-
lasting LTP than young control mice (#, p  0.05) and old control mice ($, p  0.05). Recording sessions carried out in absence of vehicle or drug administration are indicated by the
double-arrowed line. For both experiments, n ¼ 10 animals/group.
A. Giralt et al. / Neuropharmacology 123 (2017) 395e409 401modulation of short-term plastic effect by S 47445 in alert behaving
mice in the present conditions.
3.3. LTP evoked at the CA3-CA1 synapse in young alert behaving
mice following the acute administration of S 47445
AMPA-PAMs, by enhancing AMPA-mediated synaptic responses,
were demonstrated to modulate LTP in ex vivo hippocampal slices
(Lauterborn et al., 2016; Rex et al., 2005). The main feature of our
study was to assess the effect of S 47445 on this synaptic plastic
phenomenon in alert behaving mice.
Changes in the amplitude of the fEPSP slopes evoked at the CA3-CA1 synapse further to HFS protocol were followed in both groups
(young control mice and S 47445-treated mice) up to five days after
treatment (Fig. 3F). As expected, a clear potentiation of the synaptic
response evoked by the HFS protocol was observed during the first
recording day in the control group. Besides, acute administration of
S 47445 at 10 mg/kg induced a significantly larger LTP at the CA3-
CA1 synapse during the first recording day as compared with the
control group [F(118,1062) ¼ 1.716; p < 0.001]. This effect was seen
immediately after the induction of LTP and lasted for 40 min. In
contrast, no significant LTP differences were found between the S
47445 3 mg/kg group and the control group (p  0.051), although
larger fEPSP slope values were observed.
Fig. 6. Analysis of spinophilin-positive synaptic clusters in the stratum radiatum of CA1 and CA3 in vehicle- and S 47445-chronically treated mice. The number and size of the
synaptic marker spinophilin were analyzed using confocal microscopy in young control mice, old control mice, and old mice treated with S 47445 (3 mg/kg and 10 mg/kg). The
localization of the imaging analysis in the stratum radiatum is illustrated in the CA1 (A) and CA3 (D). Corresponding analyses of the number in the CA1 (B) and CA3 (E) areas, and
size in the CA1 (C) and CA3 (F) areas, of the spinophilin-positive clusters are shown. Bars represent mean ± SEM. (n ¼ 5 per group). *, p < 0.05 and **, p < 0.01 with respect to young
control mice; $$, p < 0.01 with respect to old control mice. Calibration bars are 350 mm for low magnification and 40 mm for high magnification. Abbreviations: CA1-3, cornus
ammonis 1-3; DG, dentate gyrus; Y/C, Young/control; O/C, Old/control; O/3 mg/kg, Old/3 mg/kg; O/10 mg/kg, Old/10 mg/kg.
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following acute and chronic administrations of S 47445 at 3 mg/kg
First, a comparison was performed between young control mice
and old animals treated either with vehicle (control) or with S
47445 at 3 mg/kg in acute administration. For this purpose, fEPSPsevoked at the CA3-CA1 synapse in response to the first presentation
of the HFS protocol were followed for up to two days after acute
treatment administration (Fig. 4A). As illustrated in Fig. 4B, an
overall significant effect on LTP was observed in the three groups
[F(76,1169) ¼ 2.197; p < 0.001] at the two recording sessions per-
formed on day 1 after HFS (p  0.05). During these recording
Fig. 7. Analysis of VGlut1-positive synaptic clusters in the stratum radiatum of CA1 and CA3 in vehicle- and S 47445-chronically treated mice. The number and size of the
synaptic marker VGlut1 were analyzed using confocal microscopy in young control mice, old control mice, and old mice treated with S 47445 (3 mg/kg and 10 mg/kg). The
localization of the imaging analysis in the stratum radiatum is illustrated in the CA1 (A) and CA3 (D) areas. Corresponding analyses of the number in the CA1 (B) and CA3 (E) areas
and size in the CA1 (C) and CA3 (F) areas of the VGlut1-positive clusters in the CA1 are shown. Bars represent mean ± S.EM. (n ¼ 5 per group). **, p < 0.01 and ***, p < 0.001 with
respect to young control mice; $, p < 0.05, $$, p < 0.01 and $$$, p < 0.001 with respect to old control mice; ##, p < 0.01 with respect to old mice treated with S 47445 at 3 mg/kg.
Calibration bars are 350 mm for low magnification and 40 mm for high magnification. Abbreviations: CA1-3, cornus ammonis 1-3; DG, dentate gyrus; Y/C, Young/control; O/C, Old/
control; O/3 mg/kg, Old/3 mg/kg; O/10 mg/kg, Old/10 mg/kg.
A. Giralt et al. / Neuropharmacology 123 (2017) 395e409 403sessions, old control mice displayed a marked deficit of LTP as
compared with young control mice (p  0.05). It is shown that S
47445 at 3 mg/kg administered in old mice partly corrected the LTP
deficit during the second recording day (p  0.05) with larger and
longer-lasting fEPSP slope values than those obtained in the oldcontrol group, but smaller (p  0.05) than those reached by the
young control group (Fig. 4B).
A second HFS protocol was carried out in the same animals to
study the chronic effects of the compound (at a dose of 3 mg/kg)
after a 13-day administration (Fig. 4A). The young control and the
Fig. 8. Analysis of spinophilin-positive synaptic clusters in the cortical layers II/III and V in vehicle- and S 47445-chronically treated mice. The number and size of the synaptic
marker spinophilin were analyzed using confocal microscopy in young control mice, old control mice, and old mice treated with S 47445 (3 mg/kg and 10 mg/kg). The imaging
analysis was carried out in layer II/III (A) and layer V (D) and VI of the frontal cortex. Corresponding analyses of the number in layer II/III (B) and in layer V/VI (E) and size in layer II/
III (C) and in layer V/VI (F) of the spinophilin-positive clusters are shown. Bars represent mean ± SEM. (n ¼ 5 per group). ***, p < 0.001 with respect to young control mice; $, p < 0.05
and $$, p < 0.01 with respect to old control mice. Calibration bars are 350 mm for lowmagnification and 40 mm for high magnification. Abbreviations: LI-VI, layers I, II/III, IV, V and VI;
Y/C, Young/control; O/C, Old/control; O/3 mg/kg, Old/3 mg/kg; O/10 mg/kg, Old/10 mg/kg.
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respect to baseline values. Nevertheless, the LTP evoked in the three
groups was much smaller than those collected during the previous
acute experiment (Fig. 4B and C). Similar occlusion phenomena
have been reported in cortical synapses depending on the time
interval between successive experimentally-evoked LTP (Madro~nalet al., 2007) and on HFS patterns (Ballesteros et al., 2016). This
observation suggests a decrease of LTP-evoked phenomena at the
CA3-CA1 synapse after a second presentation of the HFS protocol.
No significant age or treatment differences were observed between
the three experimental groups after chronic administration of
either vehicle or S 47445 at 3 mg/kg in young or old mice
Fig. 9. Analysis of VGlut1-positive synaptic clusters in the cortical layers II/III and V in vehicle- and S 47445-chronically treated mice. The number and size of the synaptic
marker VGlut1 were analyzed using confocal microscopy in young control mice, old control mice, and old mice treated with S 47445 (3 mg/kg and 10 mg/kg). The imaging analysis
was carried out in layer II/III (A) and layer V (D) and VI of the frontal cortex. Corresponding analyses of the number in layer II/III (B) and layer V/VI (E) and size in layer II/III (C) and
layer V/VI (F) of the VGlut1-positive clusters are shown. Bars represent mean ± SEM. (n ¼ 5 per group). *, p < 0.05, **, p < 0.01 and ***, p < 0.001 with respect to young control mice;
$$, p < 0.01 with respect to old control mice; ##, p < 0.01 with respect to old mice treated with S 47445 at 3 mg/kg. Calibration bars are 350 mm for low magnification and 40 mm for
high magnification. Abbreviations: LI-VI, layers I, II/III, IV, V and VI; Y/C, Young/control; O/C, Old/control; O/3 mg/kg, Old/3 mg/kg; O/10 mg/kg, Old/10 mg/kg.
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3.5. LTP evoked at the CA3-CA1 synapse in old alert behaving mice
following acute and chronic administrations of S 47445 at 10 mg/kg
The same procedure was followed with the dose of S 47445 at10 mg/kg administered in old mice in comparison with young
control mice and old control mice (Fig. 5A). As previously observed,
a great and significant LTP deficit was observed in old control mice
as compared with young control mice during all recording sessions
performed on day 1 [F(76,1052) ¼ 3.485; p < 0.001]. Furthermore, old
control mice did not present any significant LTP following the HFS
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mice, a complete reversion of this LTP deficit was observed on day 1,
since values were similar to those of young control mice and with a
significant difference versus old control mice (p  0.05) (Fig. 5B). In
addition, old mice treated with S 47445 at 10 mg/kg showed
significantly larger fEPSP values on the second recording day
(p  0.05) (Fig. 5B).
After chronic treatment, a significant LTP was monitored in
young control mice and old mice treated with S 47445 at 10 mg/kg
during all recorded sessions of day 1 [F(112,1538) ¼ 2.24; p < 0.001].
Similarly, we observed that the LTP evoked in each mice group was
much smaller than those collected during the previous acute
experiment (p  0.05) (Fig. 5C). This observation suggests a loss of
LTP-evoked phenomena at the synapse after a second presentation
of the HFS protocol. Interestingly, the chronic administration of S
47445 at 10 mg/kg in old mice induced significantly larger LTP
values than those in young control and old control mice during all
recorded sessions of day 1 (p  0.05) (Fig. 5C). Furthermore, this
drug effect was maintained during the two following treatment
days after the HFS protocol and also during 2 days after the end of
the treatment with S 47445 at 10 mg/kg (p  0.05) (Fig. 5C), sug-
gesting a potentially sustained effect of the drug on LTP after
repeated administration. Overall, these results indicate that young
and old mice present smaller LTPs during a second HFS session, a
deficit that was significantly compensated after chronic adminis-
tration of S 47445 at 10 mg/kg.
3.6. Hippocampal age-dependent loss of synaptic markers is
prevented by chronic S 47445 treatment
Since hippocampal LTP can be dependent on the synaptic con-
tent, the number and size of VGlut1-and spinophilin- (synaptic
markers) positive particles were evaluated in young and old control
mice as well as in old mice treated with S 47445 (3 mg/kg and
10 mg/kg). We focused on the stratum radiatum of the CA1 and
CA3, based on the results obtained in the electrophysiology and LTP
experiments.
First, we observed that, as compared with young control mice,
old control mice displayed a significant decrease in the number and
size of spinophilin-positive clusters in the stratum radiatum of the
CA1 (Fig. 6AeC) (for spinophilin number, significant group effect
[F(3,16) ¼ 3.975; p < 0.05], post hoc p < 0.05; for spinophilin size-
positive clusters, significant group effect [F(3,16) ¼ 4.291;
p < 0.05], post hoc p < 0.05).
After 30-day administration in old mice, S 47445 at 3 mg/kg had
no effect on number and size of spinophilin-positive clusters in CA1
as compared with old control mice. A trend to increase in both
number and size of spinophilin-positive particles was observed
after administration of S 47445 at 10 mg/kg, without reaching
statistical significance as compared with old control mice. In
addition, a treatment effect could be suggested since the number
and size of spinophilin-positive particles were not different be-
tween oldmice treatedwith S 47445 at 10mg/kg and young control
mice.
In the stratum radiatum of the CA3, as observed for the CA1 area,
old control mice displayed a significant reduction in number and
size of spinophilin-positive clusters as compared with young con-
trol mice (Fig. 6DeF) (for spinophilin number, significant group
effect [F(3,15) ¼ 3.659; p < 0.05], post hoc p < 0.05); for spinophilin
size-positive clusters, significant group effect [F(3,16) ¼ 4.987;
p < 0.05], post hoc p < 0.05). Interestingly, treatment with 10 mg/kg
of S 47445 significantly corrected the age-dependent deficit in the
number of spinophilin puncta in old mice as compared with old
control mice (Fig. 6E) (p < 0.001), while S 47445 at 3 mg/kg and
10 mg/kg administered in old mice partially corrected the age-dependent reduction in the size of spinophilin-positive puncta as
compared with old control mice, but without reaching statistical
significance (Fig. 6F).
In addition, we evaluated number and size of post-synaptic-
terminal positive particles for VGlut1 in the stratum radiatum of
CA1 and CA3 areas.
In the stratum radiatum of CA1, a significant decrease in the
number and size of VGlut1-positive clusters was observed in old
control mice as compared with young control mice (Fig. 7A and B)
(for number of VGlut1-positive clusters, significant group effect
[F(3,16)¼ 10.59; p < 0.001], post hoc p < 0.001; for the size of VGlut1-
positive clusters, significant group effect [F(3,16) ¼ 11.03; p < 0.001],
post hoc p < 0.01). Interestingly, old mice treated with both 3 mg/kg
and 10 mg/kg of S 47445 displayed a significant increase in the
number of VGlut1-positive clusters as compared with old control
mice (p < 0.05 and p < 0.01, respectively per dose). A complete
reversion of this age deficit was observed at the 10 mg/kg dose of S
47445 (Fig. 7B). Furthermore, old mice treated with S 47445 at
3mg/kg and 10mg/kg showed a significant size recovery of VGlut1-
positive clusters, reaching levels detected for young control mice
(p < 0.01 and p < 0.001, respectively per dose) (Fig. 7C).
We also evaluated VGlut1-positive particles in the stratum
radiatum of the CA3 (Fig. 7DeF). A strong reduction in the number
and size of these synaptic clusters (Fig. 7EeF) was found in the old
control mice as compared with young control mice (for number,
group effect [F(3,16) ¼ 30.71; p < 0.001], post hoc p < 0.001); for size,
group effect [F(3,16) ¼ 7.955; p < 0.01], post hoc p < 0.01). Interest-
ingly, a chronic administration of S 47445 at 3 mg/kg and 10 mg/kg
in old mice significantly induced recovery of VGluT1 number
(p < 0.05 and p < 0.001, respectively per dose) but only the
administration of 10 mg/kg induced a recovery of VGluT1 particle
size (p < 0.01) as compared with old control mice.
Altogether, these data suggest that chronic administration of S
47445 can increase the number and size of spinophilin- and
VGlut1-positive clusters in the CA1-CA3 areas in old mice, with a
maximum effect at 10 mg/kg dose of S 47445.
3.7. Age-dependent loss of synaptic markers in frontal cortex is
significantly ameliorated by chronic treatment with S 47445
The effects of S 47445 on spinophilin- and VGlut1-positive
clusters were also studied in another brain region involved in the
regulation of emotional and cognition changesdi.e. the frontal
cortex, more particularly in different cortical layers (Layers II/III and
V/VI).
First, number (Fig. 8B) and size (Fig. 8C) of spinophilin-positive
synaptic clusters were analyzed in layer II/III in all groups. No sig-
nificant group effect was observed in either the number
[F(3,16) ¼ 1.937; p ¼ 0.164] or the size [F(3,16) ¼ 2.791; p ¼ 0.074] of
spinophilin-positive puncta, indicating that this marker is not
affected by ageing. In the cortical layer V/VI (Fig. 8E, F), a change
was observed in the number, but not in the size [F(3,16) ¼ 0.627;
p ¼ 0.607], of spinophilin-positive particles [F(3,16) ¼ 9.422;
p < 0.001]. The corresponding post hoc analysis revealed a signifi-
cant decrease in the number of clusters in old control mice as
compared with young control mice (p < 0.001). Moreover, a sig-
nificant recovery was observed in the old mice treated with S
47445 at 3 mg/kg and 10 mg/kg as compared with old control mice
(p < 0.05 and p < 0.01, respectively per dose).
Although the changes in the spinophilin marker were discrete in
the cortex, the VGlut1 marker displayed changes in line with those
observed in the hippocampus. First, in layer II/III, VGlut1-positive
cluster number (Fig. 9B), but not size (Fig. 9C), was severely
altered between groups (number [F(3,15) ¼ 7.577; p < 0.01]; size
[F(3,16) ¼ 2.211; p ¼ 0.126]). The number of VGlut1-positive puncta
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mice (p < 0.01). S 47445 given at 3 mg/kg tended to increase the
number of VGlut1-positive puncta as compared with the value in
old control mice, but without reaching statistical significance. In
contrast, S 47445 given at 10 mg/kg in old mice demonstrated a
significant rescue of the age deficit (p < 0.01). In the cortical layer V/
VI, similar data were obtained: the number of VGlut1-positive
puncta was significantly reduced in old control mice (Fig. 9E)
[F(3,15) ¼ 14.46; p < 0.001), but not the size [F(3,16) ¼ 1.613;
p ¼ 0.225] (Fig. 9F). Here again, a significant effect was observed
following chronic administration of S 47445 at 10 mg/kg, with a
significant correction of the age-dependent deficit (p < 0.01), nearly
reaching the young-vehicle levels. In fact, there were no significant
differences between young-vehicle and 10 mg/kg old mice.
In conclusion, in the frontal cortex an age-dependent deficit was
observed for the number, but not for the size, of spinophilin- and
VGlut1-positive particles. Interestingly, with S 47445 treatment
there was a complete or almost complete reversion of the age-
dependent deficit with the dose of 10 mg/kg for each respective
synaptic marker.
4. Discussion
The present results provide evidence that chronic treatment
with S 47445, a selective positive allosteric modulator selective of
AMPA receptors, ameliorates or even completely rescues synaptic
plasticity (LTP) and synaptic cytoarchitecture (spinophilin, VGlut1
particles) deficits observed in hippocampal excitatory synapses in
old (14-month-old) mice as compared with young (3-month-old)
mice.
Firstly, the acute effects of S 47445 in young mice were evalu-
ated. At this age (3 months) hippocampal LTP induction and
expression is already highly remarkable (Griffin et al., 2006; Gruart
et al., 2006, 2008; Rex et al., 2005). LTP, along with other forms of
synaptic plasticity, is generally considered the closest neural model
for the cellular mechanism involved in learning and memory
storage. Herein, we studied the effects of evoking LTP at CA3eCA1
hippocampal synapses, knowing that pyramidal neurons in areas
CA3 and CA1 undergo both dendritic and synaptic modifications
involved in hippocampal functionsdnotably learning and memory
(Kumar, 2011; Leuner and Gould, 2010).
In the studied young mice, a temporary LTP increase induced by
S 47445 was observed only with the highest dose (10 mg/kg),
showing that in youngmicewith no LTP deficit, the drug can induce
significant changes. This effect in young mice led us to focus on
aged mice, where we found notable potentiation effects. First, in
aged (14-months-old) animals, we observed that LTP was almost
impossible to induce as compared with young mice, indicating that
synaptic plasticity is compromised at advanced ages, as described
elsewhere (Griffin et al., 2006; Gruart et al., 2008; Rex et al., 2005).
Specifically, it was reported that LTP induced with theta-burst
stimulation in basal dendrites of hippocampal field CA1
decreased rapidly in slices prepared frommiddle-aged or aged rats,
but not in slices from young adults (Lauterborn et al., 2016; Rex
et al., 2005).
This age-dependent progressive lack of LTP expression corre-
lates with age-dependent cognitive decline in either wild-type old
animals or genetically manipulated animals (Gruart et al., 2008;
Huh et al., 2016; Lin et al., 2014).
In the studied old mice, treatment with S 47445 at low dose
(3 mg/kg) significantly, but not completely, improved LTP during
day 1 after an acute treatment but had no longer-lasting effects,
even when mice were chronically treated, indicating a short-term
effect for LTP potentiation at this dose in aged mice. Furthermore,
the higher dose (10 mg/kg) induced long-lasting LTP effects evenafter an acute administration. Interestingly, the most remarkable
effect was that in mice chronically treated with 10 mg/kg, the
synapses remained potentiated during the entire treatment (1
month) and even 3 days after the last administration.
The observed long-lasting effect of S 47445 on LTP as assessed in
the CA3-CA1 synapse of alert behaving mice suggests that the drug
triggers some long-term event(s) beyond AMPA-type glutamate
receptors, and may also indicate that administration of S 47445
allows a sustained improvement in synaptic plasticity over a long
period of time. A similar enhancement of induction and mainte-
nance of LTP was previously demonstrated in the dentate gyrus of
the hippocampus of anesthetized rats after acute administration of
S 47445 at a 30 mg/kg dose (Louis et al., 2015).
One putative mechanism for this sustained effect could be
mediated through brain-derived neurotrophic factor (BDNF) since
2-week treatment with 47445 corrects the BDNF age-related defi-
cits in dorsal hippocampus and prefrontal cortex of aged rats
(Calabrese et al., 2017). This explanation makes sense since up-
regulated BDNF expression can support the formation, retention
and recall of hippocampal-related memory, and synaptic plasticity
(Bekinschtein et al., 2008; Zagrebelsky and Korte, 2014).
Our data are in line with those of other AMPA-PAMs producing
selective modulation of AMPAR-mediated currents in hippocampal
slice culture as well as an enhancement of the induction of LTP in
anesthetized rodent brains (Baudry et al., 2012; Rex et al., 2005;
Staubli et al., 1994). Staubli et al. (1994) initially reported that a
benzamide compound reversibly increased the amplitude and
prolonged the duration of field excitatory postsynaptic potentials in
hippocampal slices in normal rats. In addition, the AMPA-PAM
CX614 (Partin, 2015) in vitro was shown to enhance LTP in the
basal dendrites in the hippocampus of middle-aged rats. Also, LTP
in middle-aged rat slices, when induced in the presence of CX614,
had the same size and stability as LTP in young adults (Rex et al.,
2005). Besides, in vivo, the AMPA-PAM CX929 (5 mg/kg, 5 days)
selectively improved disturbance in the delayed consolidation of
LTP in a mouse neurodegenerative model with cognitive impair-
ment (Baudry et al., 2012). Interestingly, it has been demonstrated
that in middle-aged (8- to 13-month-old) rats, a treatment with
CX929 (5 mg/kg, 5 days), as compared with vehicle treatment, re-
stores stabilization of basal dendritic LTP (Rex et al., 2006) and
stabilizes theta-burst stimulation-induced LTP (Lauterborn et al.,
2016) in hippocampal slices. Here we show the reversal of age-
dependent LTP deficit after S 47445 administration in alert
behaving mice.
Analyzing the number and size of VGlut1-and spinophilin-
positive synaptic particles in the stratum radiatum of the CA3
areas in the hippocampus and frontal cortex, we observed im-
provements in the pre- and post-synaptic compartments of excit-
atory synapses in old mice treated with 10 mg/kg of S 47445, but
also (although to a lesser extent) in old mice treated with 3 mg/kg
of S 47445.
We report for the first time, to our knowledge, a significant
decrease in the size and number of pre- (VGlut1-positive) and post-
(spinophilin-positive) synaptic particles in both the hippocampus
and the frontal cortex of aged mice. These deficits correlate well
with LTP, dendritic and spine remodeling, and cognitive tasks also
affected by ageing (Bloss et al., 2010, 2011; Griffin et al., 2006; Rex
et al., 2006). Furthermore, levels of both VGlut1 and spinophilin are
involved in cognitive skills during different memory tasks
(Balschung et al., 2010; Cheng et al., 2011; Stafstrom-Davis et al.,
2001).
Here, a series of strong correlations was observed. First, the
severity of LTP expression was in accordance with the decrease in
the number and size of VGlut1 or spinophilin immunoreactive
spines. These variables were, at the same time, negatively
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47445 (10 mg/kg) induced a better recovery of LTP expression and
VGlut1 and spinophilin immunoreactive spine number and size in
old mice. Thus, it can be suggested that the observed improvement
in synaptic plasticity in old animals could be related to a long-
lasting modulation of VGlut1 and spinophilin in the hippocampus
and the frontal cortex.
This is in agreement with results obtained with the AMPA-PAM
CX929, which is able to offset the age-related retraction of dendritic
branches in CA1 pyramidal cells after chronic administration,
together with a greater LTP in ampakine-treated rats (Lauterborn
et al., 2016).
Moreover, expression of VGlut1 can regulate the efficacy of
glutamatergic neurotransmission since it is responsible for the
vesicular storage of L-glutamate as has been shown in VGluT1-
knock-out mice, which exhibit a loss of glutamatergic trans-
mission. Furthermore, it has been demonstrated that excitatory
transmission in the stratum radiatum of VGLUT1 knockout brain
was depressed more rapidly during 10 Hz stimulation and recov-
ered more slowly than in wild-type animals (Fremeau et al., 2001,
2004). We also observed an improvement of the synaptic archi-
tecture mediated by the higher dose of S 47445 in another brain
region (the frontal cortex) in old mice. It should be noted that the
projection of neurons extending from the CA1 region of the hip-
pocampus to the prefrontal cortex is critically involved in aspects of
cognition related to executive function and to emotional regulation,
and is a potentially crucial element of the pathophysiology of
several neuropsychiatric diseases (Godsil et al., 2013).
The latter result suggests that S 47445 has the potential to
improve synaptic connectivity in other brain regions and, as a
consequence, the cognitive function related to these, making this
drug attractive for putative systemic treatments of neurological
impairments. This is in line with the central role played by AMPA-
receptor trafficking in beta-amyloid (Ab) -induced disruption of
synaptic structure and function (Hsieh et al., 2006).
5. Conclusion
Overall, it was observed that the AMPA-PAM S 47445 displays
beneficial effects on synaptic plasticity and connectivity in the
hippocampus and the frontal cortex of alert behaving old mice
whichmay support thememory-enhancing properties of S 47445. S
47445 was shown to improve episodic-like memory as assessed in
the novel object recognition test, the spatial discrimination task,
and hippocampal-dependent contextual and serial discrimination
tasks, and to improve working memory as evaluated in several
mazes in both adult and aged rodents (Louis et al., 2015). Accord-
ingly, S 47445 could be a promising compound for improving
various forms of cognitive decline. Furthermore, we show in the
present study that S 47445 exerts positive long-lasting effects on
LTP without disturbing basic synaptic physiology in the hippo-
campus. Therefore, no seizure events are expected after S 47445
administration, in line with previous data showing no noticeable
CNS side-effects of the drug (Louis et al., 2015).
Finally, S 47445 may provide beneficial effects for the treatment
of CNS diseases associated with glutamatergic alterations, such as
Parkinson's disease, Huntington's disease, Alzheimer's disease,
and/or Major Depressive Disorder.
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